Pipeline Preview (May 2006)


Approvable designations

Approvable designations

• Sitaxsentan (Thelin, Encysive Pharmaceuticals) for the treatment of pulmonary arterial hypertension

Fast-track designations

Priority review

• Infliximab (Remicade, Centocor) for pediatric Crohn's disease

Orphan drug designations

• Cell-permeable peptide (AM-111, Auris Medical) for acute sensorineural hearing loss

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.